SCHEMBL6484935

SCHEMBL6484935

O=C(O)c1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 2/20 0.49
CDK4 P11802 1/20 0.49
MAPK8 P45983 8/20 0.49
MAPK9 P45984 7/20 0.49
MAPK14 Q16539 4/20 0.47
MAPK13 O15264 1/20 0.47
MAPK12 P53778 1/20 0.47
MAPK11 Q15759 1/20 0.47
GSK3B P49841 4/20 0.44
PRKD3 O94806 2/20 0.44
MAP4K4 O95819 2/20 0.44
MAPK1 P28482 2/20 0.44
CSNK1A1 P48729 2/20 0.44
GSK3A P49840 2/20 0.44
CSNK1G2 P78368 2/20 0.44
TAOK1 Q7L7X3 2/20 0.44
MINK1 Q8N4C8 2/20 0.44
PRKD2 Q9BZL6 2/20 0.44
CSNK1G1 Q9HCP0 2/20 0.44
CSNK1G3 Q9Y6M4 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14593078 0.92 MAPK14 (0.53) CSNK1DCDK4MAPK8MAPK9MAPK14
SCHEMBL6490443 0.91 CSNK1D (0.48) CSNK1DCDK4MAPK8MAPK9MAPK14
SCHEMBL6484913 0.90 MAPK8 (0.53) CSNK1DCDK4MAPK8MAPK9MAPK14
SCHEMBL5385928 0.85 MAPK14 (0.54) CSNK1DCDK4MAPK8MAPK9MAPK14
SCHEMBL5725033 0.84 MAPK8 (0.47) CSNK1DCDK4MAPK8MAPK9MAPK14
SCHEMBL5388522 0.83 MAPK14 (0.56) CSNK1DCDK4MAPK8MAPK9MAPK14
Gw561436X SCHEMBL5382218 0.83 MAPK14 (0.57) CSNK1DCDK4MAPK8MAPK9MAPK14
SCHEMBL5726204 0.82 CSNK1D (0.51) CSNK1DCDK4MAPK8MAPK9MAPK14
SCHEMBL6486063 0.81 CSNK1D (0.53) CSNK1DCDK4MAPK8MAPK9MAPK14
SCHEMBL5726162 0.81 CSNK1D (0.51) CSNK1DCDK4MAPK8MAPK9MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107400-A1 Use of pyrazolopyridines as therapeutic compounds SMITHKLINE BEECHAM CORPORATION 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107400-A1 Use of pyrazolopyridines as therapeutic compounds QDPR, DPYD, ENTPD5 CSNK1D 2789/4885CDK4 439/4885MAPK8 1906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.